Arcellx (ACLX) EBITDA (2021 - 2025)
Arcellx's quarterly EBITDA came in at -$58.0 million in Q4 2025, down 20.45% year-on-year from -$72.9 million in Q4 2024, and down 4.5% quarter-over-quarter from -$55.5 million in Q3 2025.
Arcellx has reported EBITDA for 5 years, with the latest figure at -$58.0 million in Q4 2025.
- For the quarter ending Q4 2025, EBITDA fell 20.45% year-over-year to -$58.0 million; the trailing twelve-month figure through Dec 2025 stood at -$228.9 million (down 113.87% YoY), and the FY2025 full-year result was -$228.9 million, down 113.87% from the prior year.
- EBITDA for Q4 2025 stood at -$58.0 million, down from -$55.5 million in the prior quarter.
- The five-year high for EBITDA was $20.5 million in Q4 2023, with the low at -$93.0 million in Q3 2022.
- Average EBITDA over 5 years is -$33.0 million, with a median of -$27.3 million recorded in 2023.
- Year-over-year, EBITDA surged 152.7% in 2023 and tumbled 656.56% in 2025.
- Tracing ACLX's EBITDA over 5 years: stood at -$20.7 million in 2021, then slumped by 87.64% to -$38.8 million in 2022, then jumped by 152.7% to $20.5 million in 2023, then plunged by 335.3% to -$48.1 million in 2024, then decreased by 20.45% to -$58.0 million in 2025.
- The last three EBITDA figures came in at -$58.0 million (Q4 2025), -$55.5 million (Q3 2025), and -$53.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -57.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.98 Mn |
| Sep 30, 2025 | -55.48 Mn |
| Jun 30, 2025 | -53.02 Mn |
| Mar 31, 2025 | -62.47 Mn |
| Dec 31, 2024 | -48.13 Mn |
| Sep 30, 2024 | -23.18 Mn |
| Jun 30, 2024 | -27.48 Mn |
| Mar 31, 2024 | -8.26 Mn |
| Dec 31, 2023 | 20.46 Mn |
| Sep 30, 2023 | -39.39 Mn |
| Jun 30, 2023 | -23.95 Mn |
| Mar 31, 2023 | -27.04 Mn |
| Dec 31, 2022 | -38.81 Mn |
| Sep 30, 2022 | -93.01 Mn |
| Jun 30, 2022 | -30.99 Mn |
| Mar 31, 2022 | -26.07 Mn |
| Dec 31, 2021 | -20.69 Mn |
| Sep 30, 2021 | -17.10 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |